Absorption, distribution, metabolism, and excretion of [14C]BYL719 (alpelisib) in healthy male volunteers
- 8 August 2015
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 76 (4), 751-760
- https://doi.org/10.1007/s00280-015-2842-4
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Phase I Study of the Pi3K&Agr; Inhibitor Byl719, As a Single Agent in Patients with Advanced Solid Tumors (Ast)Annals of Oncology, 2014
- Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical TrialsMolecular Cancer Therapeutics, 2014
- Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway InhibitorsMolecular Cancer Therapeutics, 2014
- Abstract P2-16-14: Preliminary safety, pharmacokinetics and anti-tumor activity of BYL719, an alpha-specific PI3K inhibitor in combination with fulvestrant: Results from a phase I studyCancer Research, 2013
- Safety, pharmacokinetics, and preliminary activity of the α-specific PI3K inhibitor BYL719: Results from the first-in-human study.Journal of Clinical Oncology, 2013
- Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluationBioorganic & Medicinal Chemistry Letters, 2013
- The emerging mechanisms of isoform-specific PI3K signallingNature Reviews Molecular Cell Biology, 2010
- Targeting PI3K signalling in cancer: opportunities, challenges and limitationsNature Reviews Cancer, 2009
- Targeting the phosphoinositide 3-kinase pathway in cancerNature Reviews Drug Discovery, 2009
- Mass Balance Studies, with a Focus on Anticancer DrugsClinical Pharmacokinetics, 2006